William Blair Initiates Revolution Medicines (RVMD) at Outperform

William Blair reiterated its Outperform rating on Revolution Medicines, Inc. (RVMD) on October 16, 2026. This comes as the stock was recently trading around $182.01.

Other Institutional Activity in Revolution Medicines

Several other institutional investors have shown interest in Revolution Medicines. Blackrock Inc. holds 13,695,790 shares valued at approximately $2.44 billion after increasing its holdings by 2,483,518 shares, a 22.1% rise. FMR, LLC also grew its stake by 3,736,136 shares to 12,200,422 shares, worth about $2.17 billion, reflecting a 44.1% increase. Meanwhile, Baker Bros. Advisors, LP added 1,888,116 shares, bringing its total to 11,443,357 shares valued at around $2.04 billion, a 19.8% growth.

Revolution Medicines, Inc. Stock Down 4.7%

Revolution Medicines shares are currently trading at $182.01, showing strength in a market where the company is developing innovative therapies. The stock is positioned in the biotechnology sector, focusing on treatments for RAS-addicted cancers.

Recent Earnings

Revolution Medicines reported an EPS of -$8.87 in its trailing twelve months, indicating that it is still in the development stage with no profits yet. The next earnings report is set for November 4, 2026, which will provide further insights into its financial health.

Insider Buying and Selling at Revolution Medicines, Inc.

Insider activity has been noted at Revolution Medicines, including Chief Financial Officer Jack Anders, who sold 20,000 shares on June 24, 2026, at an average price of $168.33, totaling about $3.37 million. Additionally, Anders bought 20,000 shares on the same day. Other insiders, Sushil Patel and Flavia Borellini, also made smaller purchases of 3,127 and 1,191 shares, respectively, on June 18, 2026.

Analysts Set New Price Targets

On October 7, 2026, Truist Securities maintained a Buy rating with a price target of $240. RBC Capital also maintained its Outperform rating, raising its target to $259 on October 8, and then further to $260 on October 14. Needham reiterated its Buy rating with a consistent target of $275 on October 15, 2026. The consensus among analysts indicates a positive outlook for Revolution Medicines, with several firms supporting the stock's potential.

About Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. It focuses on developing targeted therapies for RAS-addicted cancers, aiming to create effective treatments that address significant medical needs in oncology. The company's ongoing research and development efforts are crucial as it seeks to bring innovative solutions to the market.

Bottom Line

William Blair's reiteration of its Outperform rating aligns with a generally positive outlook from other analysts. Investors should watch for the upcoming earnings report on November 4, 2026, for more updates on Revolution Medicines' progress and financial performance.